Amgen’s Growing Immunotherapy Arsenal

| June 2, 2017

article image
When it comes to enlisting the cancer-fighting potential of the body’s immune defenses, Amgen believes versatility is a virtue. Dave Reese discusses Amgen’s growing cancer immunotherapy research capabilities. Large numbers of immune cells (T cells in particular) are frequently found within or adjacent to melanoma tumors, indicating that the tumors attract the attention—if not the action—of the immune system. True to its reputation as one of the most ‘immunogenic‘ cancers, melanoma now has more U.S. Food and Drug Administration (FDA)-approved immunotherapy (immune system-targeting) drugs than any other cancer type. As a consequence, metastatic melanoma is no longer the universally fatal disease it was even just 3 or 4 years ago.

Spotlight

Egis Pharmaceuticals PLC

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | February 17, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Comparing HydroxyChloroquine Trials

Article | February 17, 2020

One minor side effect of the pandemic is that perhaps more people will learn about what drug research and clinical trials can really be like. Today’s example: we have a clinical trial of hydroxychloroquine from Wuhan that has just published on a preprint server. What’s good is that this one is blinded, randomized, and controlled (like the earlier hydroxychloroquine which one I blogged about here from Zhejiang University, so we can actually talk about it rather than just spend all our time wondering what the heck is going on.

Read More

Pricing of drugs – at what cost?

Article | February 17, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More

Spotlight

Egis Pharmaceuticals PLC

Egis Pharmaceuticals PLC, headquartered in Budapest, Hungary, is one of the leading pharmaceutical companies operating principally in Central and Eastern Europe, Russia and the CIS region. Our history dates back to more than a century and our activities extend to every field of the pharmaceutical value chain: from R&D through the production of APIs and FPs to sales and marketing. Our products ranging from tablets to injections and galenic products are sold in almost 60 countries worldwide. Besides Hungary we sell our products under the brand name Egis in 17 countries through our network of subsidiaries and representative offices.

Events